

115TH CONGRESS  
2D SESSION

**S.** \_\_\_\_\_

To develop national milestones to measure success in curtailing the opioid epidemic.

---

IN THE SENATE OF THE UNITED STATES

Mr. MARKEY (for himself, Ms. MURKOWSKI, and Ms. HASSAN) introduced the following bill; which was read twice and referred to the Committee on \_\_\_\_\_

---

**A BILL**

To develop national milestones to measure success in curtailing the opioid epidemic.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “National Milestones  
5 to Measure Progress in Ending the Opioid Epidemic Act  
6 of 2018”.

7 **SEC. 2. NATIONAL MILESTONES TO MEASURE SUCCESS IN**  
8 **CURTAILING THE OPIOID EPIDEMIC.**

9 (a) IN GENERAL.—Not later than 180 days after the  
10 date of enactment of this Act, the Secretary of Health and

1 Human Services (referred to in this Act as the “Sec-  
2 retary”), in consultation with the Administrator of the  
3 Drug Enforcement Administration and the Director of the  
4 Office of National Drug Control Policy, shall develop na-  
5 tional indicators to measure success in curtailing the  
6 opioid epidemic, with the goal of significantly reversing the  
7 toll of opioid misuse and opioid-related morbidity and mor-  
8 tality in the United States within 5 years of such date  
9 of enactment (referred to in this section as the “national  
10 milestones”).

11 (b) NATIONAL MILESTONES TO END THE OPIOID  
12 EPIDEMIC.—The national milestones under subsection (a)  
13 shall include the following:

14 (1) The establishment of not fewer than 10 in-  
15 dicators or metrics to accurately and expediently  
16 measure progress in meeting the goal described in  
17 subsection (a)(1), which shall include—

18 (A) a reduction in fatal and non-fatal  
19 opioid overdoses;

20 (B) a reduction in emergency room visits  
21 related to opioid misuse and abuse;

22 (C) an increase in public and provider edu-  
23 cation, including a focus on reducing stigma as-  
24 sociated with opioid use disorder;

1 (D) an increase in the number of individ-  
2 uals in sustained recovery from opioid use dis-  
3 order;

4 (E) a reduction in the number of co-infec-  
5 tions associated with injection drug use, such as  
6 HIV, viral hepatitis, and endocarditis, and an  
7 expanded capacity to reduce initial infections  
8 and enhance access to treatment;

9 (F) an increase in the number of providers  
10 prescribing medically-assisted treatment for  
11 opioid use disorder in different settings, includ-  
12 ing primary care, community health centers,  
13 jails, and prisons;

14 (G) an increase in the number of harm re-  
15 duction organizations, including syringe services  
16 programs and naloxone distribution programs;

17 (H) an increase in the number of individ-  
18 uals admitted to opioid use disorder treatment;  
19 and

20 (I) additional indicators or metrics, such  
21 as metrics pertaining to specific populations, in-  
22 cluding women and children, American Indians  
23 and Alaskan Natives, individuals living in rural  
24 and non-urban areas, and justice-involved popu-  
25 lations, that would further clarify the progress

1           made in addressing the opioid misuse and abuse  
2           epidemic, as the Secretary determines appro-  
3           priate.

4           (2) A reasonable goal, such as a percentage de-  
5           crease or other specified metric, that signifies  
6           progress in meeting the goal described in subsection  
7           (a), and annual targets to help achieve that goal.

8           (c) EXTENSION OF PERIOD.—If the Secretary deter-  
9           mines that the goal described in subsection (a) will not  
10          be achieved with respect to any indicator or metric estab-  
11          lished under subsection (b)(2) within 5 years of the date  
12          of enactment of this Act, the Secretary may extend the  
13          timeline for meeting such goal with respect to that indi-  
14          cator or metric. The Secretary shall include with any such  
15          extension a rationale for why additional time is needed and  
16          a description of changes the Secretary will make in order  
17          to achieve such goal with respect to the indicator or met-  
18          ric.

19          (d) REPORTS.—During the 5-year period described in  
20          subsection (a) or such extended period as the Secretary  
21          may determine under subsection (c), the Secretary shall—

22                  (1) submit to Congress annual reports on the  
23          national milestones; and

24                  (2) make each such report publicly available.

1 (e) ANNUAL STATUS UPDATE.—Beginning one year  
2 after submission of the report under subsection (d) and  
3 for each year thereafter that a report is required under  
4 such subsection, the Secretary shall provide an update to  
5 Congress on the progress of Federal agencies in achieving  
6 the goals detailed in the national milestones. Each such  
7 update shall include—

8 (1) the total Federal investment in programs  
9 addressing the opioid epidemic and the amount in-  
10 vested in each program, both by fiscal year and, for  
11 programs created after fiscal year 2015, the total  
12 spent since the program’s creation;

13 (2) an evaluation of the most and least effective  
14 Federal programs intended to respond to the opioid  
15 crisis;

16 (3) the progress made in the first year or since  
17 the previous report, as applicable, in meeting each  
18 indicator or metric in the national milestones; and

19 (4) the Secretary’s proposal for meeting each  
20 specified indicator or metric in the proceeding year.